Q-Pharm, an Australian early phase CRO, has announced that Dr. Tufail Syed has been appointed as the new CEO of the company.
The Q-Pharm board has thanked interim CEO Michael Creevey for his excellent support and leadership during the transition period prior to Dr. Syed’s appointment.
Dr. Syed has 17 years of clinical research experience gained in academia, large pharmaceutical companies and global CROs.
Most recently, he held the role of regional head of Global Testing Services for the Asia-Pacific at Covance. Prior to that, Dr. Syed held executive and senior leadership roles at Medpace and Eli Lilly.
He trained as a physician in India before relocating to the U.S., where he did further training and worked as a medical researcher. He received an MBA from Rutgers Business School in New Jersey.
“Q-Pharm has proved itself to be a reliable partner to the clinical research enterprise over the last 15 years, through its high quality, safety and operational excellence,” Dr. Syed said. “I am delighted to join a best-in-class clinical research team that is dedicated to providing exceptional services to our clients and improving lives through clinical research.”
Under his leadership, Q-Pharm will maintain its focus on reliability and quality, while expanding activities to new markets and offerings.
Founded in 2002, Q-Pharm has built an enviable reputation in the recruitment and conduct of early-phase clinical trials. Q-Pharm’s foundations in bioequivalence, vaccine and disease challenge models in a broad range of healthy volunteer and patient-based trials have grown into widely acknowledged expertise. Q-Pharm has conducted more than 400 clinical trials in its state-of-the-art facilities located at Brisbane’s QIMR Berghofer Medical Research Institute. Q-Pharm provides comprehensive, high-quality services for its clients, and conducts clinical trials in accordance with all applicable national and international safety standards and guidelines. While safety and quality remain the heart of the business, Q-Pharm proactively seeks innovative and intelligent growth opportunities in the area of clinical trials.